This activity is provided by Forefront Collaborative.
Supported by an educational grant from Lilly USA, LLC.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Alzheimer's disease (AD) research is advancing at a fast pace in an effort to address its many diagnostic and treatment challenges. Accordingly, the expert faculty, with lecture and medical illustration, will look ahead to the future of AD care with a focus on the evolving understanding of AD pathophysiology, advances in diagnostic imaging, and the current status on the design and results of clinical trials of disease-modifying medications. The changing view of AD from a dementia to a chronic disease that progresses from a latent phase to mild cognitive impairment to functional impairment to dementia and the consequent implications in research and treatment will be at the core of each discussion.
The target audience for this educational activity is neurologists. Other healthcare professionals, including primary care physicians, geriatricians, and psychiatrists who care for patients with AD, may also benefit from participation.
Upon completion of the activity, participants should be able to:
Describe current theories of AD neurobiology, including recent developments regarding the propagation of Aβ and tau and other contributing biological factors
Evaluate appropriate use of currently available biomarker diagnostic techniques
Discuss the potential for novel diagnostics to improve sensitivity and specificity of AD diagnosis
Review the mechanism of action and clinical trial status of emerging therapeutics
There is no fee for this educational activity.
Conflict Of Interest Disclosure Policy
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s).* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Paul S. Aisen, MD Professor, Department of Neurology University of Southern California Founding Director, Alzheimer's Therapeutic Research Institute Keck School of Medicine of USC San Diego, CA
Dr. Aisen has consulted for NeuroPhage, Merck, Roche, Genentech, Abbott, Novartis, Biogen, Probiodrug, Anavex, AbbVie, CohBar, aTyr, Axovant, and CogRx and has done contracted research with Lilly and Janssen.
Dennis J. Selkoe, MD The Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School Co-Director, Center for Neurologic Diseases Department of Neurology Brigham and Women’s Hospital Boston, MA
Dr. Selkoe has ownership interest in Prothena Biosciences, Inc.
Accredited Provider Disclosure
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
Miranda Armie and Stephanie Breslan, MS, of Forefront Collaborative have no financial relationships to disclose relative to the content of this CME activity.
CME Content Review
The content of this activity was independently peer reviewed. The reviewers of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Forefront Collaborative designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
These presentations contain information on drug uses that have not been approved by the US FDA.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
To obtain credit, a score of 100% on the posttest is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.